These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 183789)

  • 1. Antilipidemic drugs. Part 6: LF 178 in man. A preliminary note on a multicenter investigation bearing on 393 subjects with pure or mixed forms of hyperlipidemia.
    Wülfert B; Majoie B; de Ceaurriz A
    Arzneimittelforschung; 1976; 26(5):906-9. PubMed ID: 183789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV).
    Rouffy J; Dreux C; Goussault Y; Dakkak R; Renson FJ
    Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of the lipid-lowering agent, procetofen, on the makeup of human biliary lipids].
    Grandjean EM; Mordasini R; Paumgartner G
    Schweiz Med Wochenschr; 1979 Apr; 109(16):601-2. PubMed ID: 219470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antilipidemic drugs. Part 2: Experimental study of a new potent hypolipidemic drug, isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF178).
    Gurrieri J; Lous ML; Renson FJ; Tourne C; Voegelin H; Majoie B; Wüfert E
    Arzneimittelforschung; 1976; 26(5):889-94. PubMed ID: 989363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J; Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
    [No Abstract]   [Full Text] [Related]  

  • 6. Antilipidemic drugs. Part 3: On the synthesis of 14C-radiolabelled isopropyl-[4'-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF-178).
    Duc CL
    Arzneimittelforschung; 1976; 26(5):894-5. PubMed ID: 989364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia.
    Olsson AG; Rössner S; Walldius G; Carlson LA
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):28-31. PubMed ID: 190607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
    Klemens UH; von Löwis P
    Dtsch Med Wochenschr; 1973 Jun; 98(24):1197-202. PubMed ID: 4350685
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperlipidemia.
    Sloan RW
    Am Fam Physician; 1983 Sep; 28(3):171-82. PubMed ID: 6613796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
    Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
    Therapie; 1978; 33(5):615-22. PubMed ID: 217121
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
    McCrindle BW; Ose L; Marais AD
    J Pediatr; 2003 Jul; 143(1):74-80. PubMed ID: 12915827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil treatment: a comparison with clofibrate.
    Howard AN; Ghosh P
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):88-9. PubMed ID: 190609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does hypolipidemic therapy prevent coronary heart disease?
    Rifkind BM; Levy RI
    Cardiovasc Clin; 1974; 6(2):1-8. PubMed ID: 4374303
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical evaluation of cinnarizine in hyperlipaemic patients.
    Saba P; Galeone F; Salvadorini F; Guarguaglini M; Houben JL
    G Clin Med; 1974 Aug; 55(8):586-99. PubMed ID: 4377134
    [No Abstract]   [Full Text] [Related]  

  • 17. [Beta-sitosterin in unsuccessfully pretreated patients with hypercholesteremia. Simultaneously, a contribution to dose dependence].
    Mühlfellner G; Mühlfellner O; Kaffarnik H
    Med Klin; 1976 Apr; 71(18):775-8. PubMed ID: 178987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should hyperlipidemia be treated? Available agents and clinical results.
    Gotto AM
    Cardiovasc Res Cent Bull; 1978; 17(1):3-27. PubMed ID: 223761
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy and tolerability of simvastatin and omega-3 fatty acid combination in patients with coronary disease, hypercholesterolemia and hypertriglyceridemia].
    Tomei R; Rossi L; Carbonieri E; Franceschini L; Cemin C; Ghebremariam-Tesfau K; Zardini P
    Cardiologia; 1993 Dec; 38(12):773-8. PubMed ID: 8200011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.